Therapy Areas: Respiratory
13 September 2019 - Switzerland-based Roche's lung cancer drug Tecentriq (atezolizumab) has improved overall survival rate in a phase III IMpower110 study, it was reported yesterday.The trial is ...
12 September 2019 - - US-based diagnostics developer Biodesix, Inc. has highlighted positive clinical data from Oncimmune's Early CDT Lung blood test, which harnesses the power of ...
11 September 2019 - United Kingdom-based AstraZeneca's Imfinzi (durvalumab) has improved overall survival (OS) in patients with earlier untreated extensive-stage small cell lung cancer (SCLC) in ...
10 September 2019 - AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, on Monday presented detailed results from the phase III CASPIAN trial, showing that Imfinzi (durvalumab)...
9 September 2019 - - French pharmaceutical company Ipsen (Euronext: IPN) (OTC: IPSEY) and pharmaceutical company Servier have presented initial safety and efficacy data from Part 1 of t...
9 September 2019 - - British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) presented detailed results from the Phase III CASPIAN trial, showing Imfinzi (durvalumab) significantly improved ov...